Merck & Co.
MRK
$143.93
-0.54%
Merck & Co., Inc. is a global healthcare leader that develops and markets pharmaceuticals, vaccines, and animal health products, with a focus on therapeutic areas including oncology, cardiometabolic disease, and infectious diseases. The company is distinguished by its immuno-oncology franchise, anchored by the blockbuster drug Keytruda, and its leading vaccine portfolio, including Gardasil, which together underpin its competitive moat in the industry. Currently, the investment narrative centers on Merck's strategic pivot to diversify beyond Keytruda's looming patent cliff, with recent positive Phase 3 data for an mRNA cancer vaccine (in partnership with Moderna) and a robust pipeline of new therapies driving renewed optimism. The stock has also been buoyed by strong financial performance and a series of analyst upgrades, reflecting confidence in its long-term growth trajectory despite ongoing regulatory and competitive pressures.…
MRK
Merck & Co.
$143.93
Related headlines
Investment Opinion: Should I buy MRK Today?
We rate Merck as a Buy, anchored by a strong pipeline and a reasonable valuation. The analyst consensus is Buy with an average target of $148.73, implying a modest -1.1% downside from the current price, but the high target of $186 suggests significant upside potential. The thesis is that Merck's diversified portfolio, including the mRNA vaccine, will offset Keytruda's decline and drive long-term growth.
Sign up to view all
MRK 12-Month Price Forecast
The AI model assesses Merck as bullish over the next 12 months, driven by the pipeline breakthrough and attractive valuation. The medium confidence reflects uncertainties around Keytruda's patent cliff and the Q1 loss. Key factors include the stock's 78.9% 1-year return, which shows strong momentum, and the potential for the mRNA vaccine to transform growth prospects. The stance would be upgraded to high confidence if the vaccine receives regulatory approval and revenue growth accelerates, while a downgrade to neutral would occur if key trials fail or Keytruda sales decline sharply.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $152.96 and implied upside of +6.3% versus the current price.
Average Target
$152.96
0 analysts
Implied Upside
+6.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $186
Analyst target range
The target price range spans from a low of $105.00 to a high of $186.00, with a wide spread of $81.00, indicating significant uncertainty about Merck's future performance. The low target of $105.00 implies a downside of -30.2% from the current price, which could reflect concerns about Keytruda's patent expiration, competitive pressures, or regulatory risks. The high target of $186.00 implies an upside of +23.7%, likely assuming successful pipeline execution, including the mRNA cancer vaccine and other key assets. The wide range suggests that analysts have divergent views on the company's growth prospects, with some being highly optimistic and others more cautious. Recent institutional ratings have been predominantly positive, with firms like BMO Capital, Guggenheim, and JP Morgan reiterating Buy or Overweight ratings in July 2026, while Morgan Stanley maintains an Equal Weight stance, indicating a balanced but generally constructive outlook.
Bulls vs Bears: MRK Investment Factors
Merck presents a compelling bull case driven by the historic mRNA vaccine breakthrough, strong financial fundamentals, and defensive qualities, but bears highlight the imminent Keytruda patent cliff and a Q1 loss that clouds near-term earnings. The bull side currently has stronger evidence because the pipeline optionality and valuation discount provide a favorable risk/reward, yet the central tension is whether Merck can successfully transition from Keytruda dependence to a diversified growth portfolio before 2028. The stock's fate hinges on the pace of pipeline execution and the market's perception of post-cliff earnings power.
Bullish
- Historic mRNA Cancer Vaccine Success: Merck and Moderna's Phase 3 trial of mRNA-4157 (V940) succeeded, marking the first mRNA cancer vaccine to hit the primary endpoint. This breakthrough could open a new multibillion-dollar market and significantly diversify Merck's oncology portfolio beyond Keytruda, with pivotal data expected within 12 months.
- Strong Momentum and Analyst Support: The stock has surged 78.9% over the past year and 17.1% in the last month, trading near its 52-week high of $156.92. Analysts maintain a Buy consensus (1.75 mean rating) with an average target of $148.73, and recent upgrades from BMO, Guggenheim, and JP Morgan underscore positive sentiment.
- Undervalued on Earnings: Merck's trailing PE of 14.42x is 22% below the industry average of 18.5x, while its forward PE of 15.75x suggests modest earnings growth. This discount appears unjustified given the pipeline potential, offering a margin of safety if execution succeeds.
- Robust Profitability and Cash Flow: Gross margins stand at 72.0%, operating margin at 36.2%, and net margin at 28.1%, reflecting strong pricing power. Free cash flow over the trailing twelve months reached $14.1 billion, providing ample resources for dividends, buybacks, and R&D investments.
Bearish
- Keytruda Patent Cliff Looming: Keytruda, Merck's top-selling drug, faces U.S. patent expiration in 2028, exposing over $25 billion in annual sales to biosimilar competition. The company's Q1 2026 revenue growth of just 4.3% YoY highlights the urgency to replace this revenue before the cliff hits.
- Q1 2026 Net Loss and One-Time Charges: Merck reported a net loss of $4.24 billion in Q1 2026, driven by a $12.56 billion R&D charge related to an in-process R&D acquisition. This resulted in negative EPS of -$1.72, a stark contrast to the $5.08 billion net income in Q1 2025, raising concerns about earnings volatility.
- High Valuation on Sales and Book Value: The price-to-sales ratio of 4.06x and price-to-book of 5.01x are elevated relative to historical norms, suggesting the market already prices in significant pipeline success. If pipeline assets disappoint, the stock could face multiple compression.
- Wide Analyst Target Range: Analyst targets range from $105 to $186, a spread of $81, indicating deep uncertainty. The low target implies a 30.2% downside from the current price, reflecting fears of Keytruda's decline and competitive threats from rivals like Summit Therapeutics' ivonescimab.
MRK Technical Analysis
Merck's stock is in a powerful uptrend, with a 1-year price change of +78.86% and a 52-week range of $77.58 to $156.92. The current price of $150.33 sits at 95.8% of the 52-week range, indicating the stock is trading near its highs, which typically signals strong momentum but also potential overextension. The sustained climb from the 52-week low, coupled with a beta of 0.226, suggests the stock is significantly less volatile than the broader market, making it a defensive growth play within healthcare.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$157
Price range past year
Annual Return
+69.0%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +8.3% | -1.1% |
| 3m | +20.9% | +3.0% |
| 6m | +24.5% | +15.4% |
| 1y | +69.0% | +16.2% |
| ytd | +35.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory shows resilience, with the most recent quarter (Q1 2026) reporting revenue of $16.29 billion, a 4.27% year-over-year increase. This growth is modest compared to the prior year's quarters, where revenue grew from $15.62 billion in Q1 2025 to $16.29 billion in Q1 2026, indicating a deceleration from the double-digit growth seen in 2024. The pharmaceutical segment, which generated $14.35 billion in Q1 2026, remains the primary growth driver, while the animal health segment contributed $1.79 billion, and other segments added $0.15 billion. The growth trajectory suggests a maturing portfolio, with Keytruda's patent cliff looming, but the company's pipeline, including the mRNA cancer vaccine, could offset this decline.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Given Merck's positive net income over the trailing twelve months, the PE ratio is the most appropriate valuation metric. The trailing PE is 14.42x, while the forward PE is 15.75x, indicating that the market expects earnings to grow modestly, as the forward multiple is slightly higher. This gap suggests that while earnings are expected to increase, the market is not pricing in explosive growth, which is consistent with the company's mature portfolio and pipeline uncertainties. The PE ratio of 14.42x is below the industry average of 18.5x (as per available data), representing a discount of approximately 22%, which could be justified by Merck's lower growth prospects compared to peers like Eli Lilly or Novo Nordisk, but it also highlights potential undervaluation if the pipeline succeeds.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable, with Merck's debt-to-equity ratio at 0.96, indicating significant leverage that could strain cash flows if interest rates remain elevated. The Q1 2026 net loss of $4.24 billion, driven by a massive R&D charge, underscores earnings volatility, while the payout ratio of 44.8% suggests dividend sustainability is tied to stable earnings. Revenue growth of just 4.3% YoY in Q1 2026 signals maturity, and the company's heavy reliance on Keytruda, which accounts for a substantial portion of pharmaceutical sales, creates concentration risk as its patent cliff approaches in 2028.